当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-09-24 , DOI: 10.1111/apt.16605 Johannes P D Schultheiss 1 , Remi Mahmoud 1 , Jonas M Louwers 1 , Michiel T van der Kaaij 1 , Boris P van Hellemondt 1 , Petra G van Boeckel 2 , Nofel Mahmmod 2 , Bindia Jharap 3 , Herma H Fidder 1 , Bas Oldenburg 1
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2021-09-24 , DOI: 10.1111/apt.16605 Johannes P D Schultheiss 1 , Remi Mahmoud 1 , Jonas M Louwers 1 , Michiel T van der Kaaij 1 , Boris P van Hellemondt 1 , Petra G van Boeckel 2 , Nofel Mahmmod 2 , Bindia Jharap 3 , Herma H Fidder 1 , Bas Oldenburg 1
Affiliation
|
Inflammatory bowel disease (IBD) is often managed with anti-tumour necrosis factor-α therapy (anti-TNFα), but treatment efficacy is compromised by high annual rates of loss of response (13%-21% per patient-year).
中文翻译：
对抗 TNFα 药物的反应丧失取决于炎症性肠病患者的治疗持续时间
炎症性肠病 (IBD) 通常通过抗肿瘤坏死因子-α 疗法 (anti-TNFα) 进行治疗，但治疗效果会因高年失反应率（每患者每年 13%-21%）而受到影响。
更新日期：2021-10-27
中文翻译：
对抗 TNFα 药物的反应丧失取决于炎症性肠病患者的治疗持续时间
炎症性肠病 (IBD) 通常通过抗肿瘤坏死因子-α 疗法 (anti-TNFα) 进行治疗，但治疗效果会因高年失反应率（每患者每年 13%-21%）而受到影响。
京公网安备 11010802027423号